...
首页> 外文期刊>The journal of clinical endocrinology and metabolism >Longevity in Untreated Congenital Growth Hormone Deficiency Due to a Homozygous Mutation in the GHRH Receptor Gene
【24h】

Longevity in Untreated Congenital Growth Hormone Deficiency Due to a Homozygous Mutation in the GHRH Receptor Gene

机译:由于GHRH受体基因中的纯合突变引起的未经治疗的先天性生长激素缺乏症

获取原文
           

摘要

Context: Reduced longevity observed in hypopituitarism has been attributed to GH deficiency (GHD). It is, however, unclear whether GHD or other confounding factors cause this early mortality.Objective: The aim was to study longevity in subjects from a large kindred with untreated, lifetime isolated GHD (IGHD) due to a homozygous mutation in the GHRH receptor gene and in heterozygous carriers of the mutation.Design, Setting, and Participants: We carried out a retrospective cohort study on three groups. We first compared mortality risk of 65 IGHD individuals and their 128 unaffected siblings from 34 families. We then compared mean age of death of the IGHD to the general population. A transversal study was carried out to compare the rate of heterozygosity for the mutation in two groups of young (20–40 yr old) and old (60–80 yr old) normal-appearing subjects from the same county.Main Outcome Measure: We measured longevity.Results: The risk of death of IGHD subjects was not different from their siblings. Life span in IGHD individuals was shorter than the general population. When stratified by sex, this difference persisted only in females, due to a high frequency of IGHD deaths in females aged 4–20. There was no significant difference in life span between IGHD subjects and siblings or the general population when analyzing subjects who reached age 20. The prevalence of heterozygosity did not differ in young and old groups, suggesting no survival advantage or disadvantage.Conclusions: In a selected genetic background, lifelong untreated IGHD does not affect longevity.
机译:背景:低质量观察到的寿命减少,归因于GH缺乏(GHD)。然而,目前尚不清楚GHD或其他混淆因素是否会导致这种早期死亡率。目的是由于GHRH受体基因中的纯合体突变,从一个大型的唯一孤立的GHD(IGHD)中研究寿命的寿命。在突变的杂合载体中。设计,设定和参与者:我们对三组进行了回顾性队列研究。我们首先比较了65名Ighd个人的死亡率风险,并从34个家庭中的128名不受影响的兄弟姐妹。然后,我们将IVED死亡的平均年龄与一般人群相比。进行了横向研究,以比较两组年轻(20-40岁)和旧(60-80岁)正常出现的突变突变率的杂合子率,从同一县。测量寿命。结果:IVED科目的死亡风险与他们的兄弟姐妹没有什么不同。 Ighd个人的寿命比一般人群短。当按性别分层时,由于4-20岁的女性的Ighd死亡频率高,这种差异仅在女性中持续存在。 Ighd科目和兄弟姐妹之间的生命跨度差异没有显着差异,或者在分析达到20岁的科目时的普通群体之间。杂合子的患病率在年轻人和旧群体中没有差异,表明没有生存的优势或缺点。结论:在选定中遗传背景,Lifelong未经治疗的Ighd不会影响寿命。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号